<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>60(2)</volume><submitter>Murray K</submitter><pubmed_abstract>&lt;h4>Objectives&lt;/h4>To establish, amongst Irish rheumatic musculoskeletal disease (RMD) patients, rates of COVID-19 symptoms and positive tests, DMARD adherence and attitudes to virtual clinics.&lt;h4>Methods&lt;/h4>An online survey assessing COVID-19 status, RMD diagnoses, adherence and information sources was disseminated via the Arthritis Ireland website and social media channels.&lt;h4>Results&lt;/h4>There were 1381 respondents with 74.8% on immunosuppressive medication. Symptoms of COVID-19 were reported by 3.7% of respondents of which 0.46% tested positive, consistent with the general Irish population. The frequency of COVID-19 symptoms was higher for respondents with spondyloarthropathy [odds ratio (OR) 2.06, 95% CI: 1.14, 3.70] and lower in those on immunosuppressive medication (OR 0.48, 95% CI: 0.27, 0.88), and those compliant with health authority (HSE) guidance (OR 0.47, 95% CI: 0.25, 0.89). Adherence to RMD medications was reported in 84.1%, with 57.1% using health authority guidelines for information on medication use. Importantly, adherence rates were higher amongst those who cited guidelines (89.3% vs 79.9%, P &lt;0.001), and conversely lower in those with COVID-19 symptoms (64.0% vs 85.1%, P =0.009). Finally, the use of virtual clinics was supported by 70.4% of respondents.&lt;h4>Conclusion&lt;/h4>The rate of COVID-19 positivity in RMD patients was similar to the general population. COVID-19 symptoms were lower amongst respondents on immunosuppressive medication and those adherent to medication guidelines. Respondents were supportive of HSE advice and virtual clinics.</pubmed_abstract><journal>Rheumatology (Oxford, England)</journal><pagination>902-906</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7717358</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.</pubmed_title><pmcid>PMC7717358</pmcid><pubmed_authors>Quinn S</pubmed_authors><pubmed_authors>O'Neill L</pubmed_authors><pubmed_authors>O'Rourke A</pubmed_authors><pubmed_authors>Turk M</pubmed_authors><pubmed_authors>Murray K</pubmed_authors><pubmed_authors>Veale DJ</pubmed_authors><pubmed_authors>Fearon U</pubmed_authors><pubmed_authors>Mongey AB</pubmed_authors><pubmed_authors>Molloy E</pubmed_authors></additional><is_claimable>false</is_claimable><name>COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.</name><description>&lt;h4>Objectives&lt;/h4>To establish, amongst Irish rheumatic musculoskeletal disease (RMD) patients, rates of COVID-19 symptoms and positive tests, DMARD adherence and attitudes to virtual clinics.&lt;h4>Methods&lt;/h4>An online survey assessing COVID-19 status, RMD diagnoses, adherence and information sources was disseminated via the Arthritis Ireland website and social media channels.&lt;h4>Results&lt;/h4>There were 1381 respondents with 74.8% on immunosuppressive medication. Symptoms of COVID-19 were reported by 3.7% of respondents of which 0.46% tested positive, consistent with the general Irish population. The frequency of COVID-19 symptoms was higher for respondents with spondyloarthropathy [odds ratio (OR) 2.06, 95% CI: 1.14, 3.70] and lower in those on immunosuppressive medication (OR 0.48, 95% CI: 0.27, 0.88), and those compliant with health authority (HSE) guidance (OR 0.47, 95% CI: 0.25, 0.89). Adherence to RMD medications was reported in 84.1%, with 57.1% using health authority guidelines for information on medication use. Importantly, adherence rates were higher amongst those who cited guidelines (89.3% vs 79.9%, P &lt;0.001), and conversely lower in those with COVID-19 symptoms (64.0% vs 85.1%, P =0.009). Finally, the use of virtual clinics was supported by 70.4% of respondents.&lt;h4>Conclusion&lt;/h4>The rate of COVID-19 positivity in RMD patients was similar to the general population. COVID-19 symptoms were lower amongst respondents on immunosuppressive medication and those adherent to medication guidelines. Respondents were supportive of HSE advice and virtual clinics.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Feb</publication><modification>2024-10-15T06:42:53.274Z</modification><creation>2021-02-20T07:36:35Z</creation></dates><accession>S-EPMC7717358</accession><cross_references><pubmed>33164088</pubmed><doi>10.1093/rheumatology/keaa694</doi></cross_references></HashMap>